Abstract
Neoadjuvant stereotactic radiosurgery (SRS) for intracerebral metastases offers potential advantages over postoperative SRS to the resection cavity, such as better target volume definition with subsequent higher efficiency of eliminating tumor cells, lower damage to surrounding healthy tissue, and more rapid initiation of systemic chemotherapy. The NepoMUC trial is a phase I dose-escalation study designed to determine the maximum tolerated dose (MTD) of pre-operative radiation for brain metastases.
Introduction
Brain metastases occur in more than 25% of patients with solid tumors, such as lung or breast cancer. The current standard of care for large or symptomatic lesions involves surgical resection followed by adjuvant radiation to the resection cavity. However, this approach faces several challenges: delayed systemic therapy due to wound healing, targeting uncertainty as the cavity collapses, risks of leptomeningeal seeding during surgery, and higher rates of radiation necrosis in healthy tissue surrounding the cavity.
The NepoMUC trial investigates a paradigm shift: delivering high-precision SRS before surgical resection. This neoadjuvant approach aims to improve targeting accuracy and reduce treatment-related toxicities.
Methods
The NepoMUC trial is a single-center, phase I study employing a traditional 3+3 dose-escalation design. Patients are stratified into four cohorts based on the size of their largest lesion, ranging from ≤1.0 cm to 4.0 cm.
Dose Escalation and Intervention
The primary goal is to find the MTD across different tumor size categories. Starting doses are based on established safety data, with 2 Gy increments planned up to the maximum recommended by German oncology guidelines.
The intervention follows a strict timeline:
- Neoadjuvant SRS: A single high-precision dose to the intact tumor.
- Surgery: Microsurgical resection performed 2 to 7 days post-radiation.
- Follow-up: Continuous monitoring for adverse events, with primary safety evaluation at 4–6 weeks post-surgery.
Study Schedule
The study follows a comprehensive schedule of assessments, including MRI/CT imaging, neurocognitive testing (MMSE), and quality of life (QoL) evaluations.
Key Insights
- Targeting Precision: Radiating an intact, contrast-enhancing tumor is technically superior to radiating a collapsed surgical cavity. This allows for tighter margins and better sparing of healthy brain tissue.
- Biological Sterilization: Pre-operative radiation may "sterilize" tumor margins, potentially reducing the risk of viable cell seeding during surgery and subsequent leptomeningeal disease.
- Efficiency of Care: By completing radiation before surgery, patients can transition to systemic chemotherapy or immunotherapy as soon as the surgical wound heals, eliminating the typical post-operative delay for radiation.
- Immunological Analysis: Resected specimens will be analyzed for markers like PD-L1 to understand how neoadjuvant radiation alters the tumor microenvironment.
Endpoints and Expected Outcomes
The primary endpoint is the determination of the MTD. Secondary endpoints include local control rates, overall survival (OS), progression-free survival (PFS), and changes in neurocognitive function. The researchers anticipate that neoadjuvant SRS will demonstrate lower rates of symptomatic radiation necrosis and leptomeningeal spread compared to historical adjuvant radiation data.
Limitations and Future Directions
As a Phase I trial, the study is limited by its single-center design and focus on safety/dosing rather than definitive efficacy. It excludes certain radiosensitive histologies and very large lesions (>4 cm). However, establishing the MTD will provide the necessary foundation for future Phase II/III randomized trials comparing neoadjuvant SRS directly to the current standard of care.
Summary updated